GlobeNewsWire
22 Sept 2026, 18:48 UTC · 1h ago
Verdict
Headline takes no side. We score ASTS −0.80 across two claims — strongly bearish.
−0.80strongly bearish
More negative than 87% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
ARS Pharmaceuticals is facing a securities class action lawsuit alleging it misled investors regarding the July 1, 2026, start date for expanded insurance coverage for its epinephrine nasal spray, neffy, via CVS Caremark.
Priced inarticle states a lawsuit has already been filed
So whatLegal liability and damaged trust regarding the primary revenue driver, neffy, could lead to downward revisions in FY2026 revenue estimates.
More negative than 87% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The deadline for investors to move the Court to serve as lead plaintiff in the ARS Pharmaceuticals class action is October 5, 2026.
Newpress release dated Sept 22
More negative than 67% of claims this week
Which stocks this story touches
More negative than 87% of ticker scores this week
The company is the subject of a class action lawsuit announced by the Rosen Law Firm.
More negative than 87% of ticker scores this week
The company is facing a securities class action lawsuit alleging false and misleading statements regarding insurance coverage for its product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
+4.3%
Price is moving against the score
$64.55 vs $61.89 close before publication (Sep 21) · not market-adjusted
ASTS chart →